Hot Mandates: Switzerland-based Venture Capital

1 Mar

A fund that was initiated in 2001 by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich. The firm invests the capital of 10 Swiss corporations, and invests in a variety of technological industries; about 50% of the firm’s portfolio companies are in the life science sector. The firm makes allocations from $500,000 to $10m over the life of the investment, and in the life science sector the firm’s allocations are typically over $5m. The firm only invests in companies based in Europe or with ties to Europe, and focuses on Switzerland and its surrounding region, including Germany, France and Austria.

The firm invests in the biotech and medtech sectors and is opportunistic within these sectors regarding indication area and technology. The firm prefers to invest in early-stage companies, with assets ranging from preclinical to mid-stage clinical trials (Phase II for therapeutics).

The firm prefers to invest in companies with ties to Switzerland, particularly those that use technology developed at a Swiss research institution, but will consider companies located in or with ties to the surrounding region. The firm seeks highly qualified, ambitious management teams, and is typically an activist investor that takes a seat on a portfolio company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: